Clinigen Group opens Global Operations Centre

Published: 14-Mar-2012
Pharmaceutical

Will improve distribution and stock levels

Clinigen Group, a global specialist pharmaceutical products and services business based in the UK, has opened a new £350,000 Global Operations Centre in Stretton, near Burton-on-Trent Staffordshire.

Peter George, chief executive of Clinigen, said: ‘We are continuing to expand and have ambitious plans for the future. It is essential that we have the right resource and facilities to service our clients, both now, and as we continue to develop.’

The firm says the new 8,000ft2 warehousing and distribution facilities will enable it to stock and distribute pharmaceutical products to its global customer base in a fast and efficient manner.

The new Operations Centre combined with the company's headquarters in Burton, have created more than 30 new jobs in recent months. In total the firm employs 300 staff.

Clinigen Group was formed in 2010 by the merger of three companies: Clinigen CTS (formerly Keats Healthcare) and Clinigen GAP, which make up Clinigen's services division, and Clinigen Healthcare, the Group's products business.

The Group operates across the clinical lifecycle of a drug, from Phase 1 clinical trials to the end of patent and beyond.

See more

You may also like

Distribution

Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally

Read more
Clinigen Group will be respsonsible for the distribution of Duchenne muscular dystrophy (DMD) treatment AGAMREE (vamorolone) in regions not currently covered by Santhera or its distribution partners

Trending Articles

  1. NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer MSD's KEYTRUDA (pembrolizumab) has received NICE approval as a neoadjuvant and adjuvant therapy for resectable LA HNSCC—the first immunotherapy recommended in this perioperative setting and the first treatment advance in more than two decades
  2. FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
  3. dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
  4. Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026 Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
  5. Wilmington PharmaTech invests $50m into US small-molecule API manufacturing plant The CRDMO will more than double the capacity in its current API reactor in Delaware, positioning itself to meet growing demand for US-based manufacturing

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

Distribution

Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally

Clinigen Group will be respsonsible for the distribution of Duchenne muscular dystrophy (DMD) treatment AGAMREE (vamorolone) in regions not currently covered by Santhera or its distribution partners
Packaging

Packaging for success

Somewhat misguidedly, pharmaceutical packaging is often overlooked or assumed to be a commodity service that “anyone can do,” says Scott Houlton, CEO, CSM (a Clinigen Group company)
Finance

Clinigen’s £225m acquisition of Idis goes ahead

Acquisition accelerates the company's growth, provides a better balanced portfolio and extends its business model
Finance

2014 Sunday Times Rich List sees entry of more pharma executives

Ernesto and Kirsty Bertarelli are still out ahead of the rest
Manufacturing

Mabwell signs Malaysia licensing deal for denosumab biosimilars MAILISHU and MAIWEIJIAN

Mabwell has entered a licensing and commercialisation agreement to bring its denosumab biosimilars to Malaysia, supporting regional access through local registration and supply of its Prolia and Xgeva reference products
Research & Development

"Miracle" Alzheimer's drugs show no meaningful benefit, says major review

Amyloid-clearing drugs hailed as a breakthrough for Alzheimer's treatment make "no meaningful difference to patients" and increase the risk of brain swelling and bleeding, according to a sweeping new Cochrane meta-analysis
Media

Aragen launches ChemiSHE, India's first women-led chemistry synthesis laboratory

The firm has inaugurated ChemiSHE, a pioneering all-women chemistry synthesis laboratory at its Hyderabad campus, as part of a broader diversity initiative targeting the addition of up to 1000 women employees across scientific and leadership roles during the next three years
Subscribe now